Intangible Assets - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Nov. 30, 2018	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2018	Mar. 04, 2022	Dec. 31, 2021		May 31, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expenses			$ 600,000	$ 1,200,000
Amortization expenses, remainder period			1,200,000	1,200,000
Amortization expenses, 2023			2,400,000	2,400,000
Amortization expenses, 2024			2,400,000	2,400,000
Amortization expenses, 2025			2,400,000	2,400,000
Amortization expenses, 2026			2,400,000	2,400,000
Amortization expenses, thereafter			19,100,000	19,100,000
Capitalization of finite-lived intangible asset			32,500,000	32,500,000			$ 47,500,000
Other accrued liabilities			31,984,000	31,984,000			30,282,000	[1]
Other long-term liabilities			28,631,000	28,631,000			22,069,000	[1]
Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc
Finite-Lived Intangible Assets [Line Items]
Capitalization of finite-lived intangible asset									$ 12,500,000
Payment Following FDA Approval of Truseltiq
Finite-Lived Intangible Assets [Line Items]
Capitalization of finite-lived intangible asset									$ 20,000,000.0
QED Therapeutics, Inc
Finite-Lived Intangible Assets [Line Items]
Other accrued liabilities			2,500,000	2,500,000			1,500,000
Other long-term liabilities			8,500,000	$ 8,500,000			11,000,000.0
QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc
Finite-Lived Intangible Assets [Line Items]
Potential regulatory milestone payments	$ 12,500,000
Regulatory milestone payments term	4 years
First installment due amount, paid			$ 1,500,000
QED Therapeutics, Inc | Maximum
Finite-Lived Intangible Assets [Line Items]
Potential regulatory milestone payments					$ 60,000,000.0
Potential sales milestone payments					35,000,000.0
Origin Biosciences, Inc.
Finite-Lived Intangible Assets [Line Items]
Potential sales milestone payments					17,000,000.0
Capitalization of finite-lived intangible asset							$ 15,000,000.0
Origin Biosciences, Inc. | Maximum
Finite-Lived Intangible Assets [Line Items]
Potential regulatory milestone payments					1,000,000.0
Assets acquisition required milestone payments					$ 18,800,000
Origin-Sentynl APA
Finite-Lived Intangible Assets [Line Items]
Derecognition of capitalized intangible asset net.		$ 13,500,000
Assets acquisition required milestone payments		$ 1,000,000.0
Origin-Sentynl APA | Maximum
Finite-Lived Intangible Assets [Line Items]
Potential sales milestone payments						$ 4,500,000

[1] The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.